BACKGROUND: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS). OBJECTIVE: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients. METHODS: Eighty-nine natalizumab-treated RRMS patients with minimum follow-up of 3 years were included. sCNTN1 was analyzed at baseline (before natalizumab initiation), 3, 12, 24 months (M) and last follow-up (median 5.2 years) and compared to 222 healthy controls (HC) and 15 primary progressive MS patients (PPMS). Results were compared between patients with progressive, stable, or improved disability according to EDSS-plus criteria. RESULTS: Median sCNTN1 levels...
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiti...
Objective: To report the relationship between disease activity and health-related quality of life (H...
Background: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activ...
Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression ...
Background: Despite highly effective treatment strategies for patients with relapsing-remitting mult...
OBJECTIVE: The objective of this study was to investigate the potential of serum neurofilament light...
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, ne...
BACKGROUND: Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS)....
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by bindi...
BACKGROUND: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarker...
Background: Multiple sclerosis (MS) is the commonest cause of non-traumatic neurological disability ...
Aim of the study Our main purpose was to investigate if the chronic treatment with the disease-modif...
In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesion...
The pathophysiology of multiple sclerosis (MS) is complex with the presence of inflammation and neur...
Abstract Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous sys...
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiti...
Objective: To report the relationship between disease activity and health-related quality of life (H...
Background: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activ...
Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression ...
Background: Despite highly effective treatment strategies for patients with relapsing-remitting mult...
OBJECTIVE: The objective of this study was to investigate the potential of serum neurofilament light...
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, ne...
BACKGROUND: Natalizumab is an effective treatment for relapsing-remitting multiple sclerosis (RRMS)....
Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by bindi...
BACKGROUND: There is a need in Relapsing-Remitting Multiple Sclerosis (RRMS) treatment for biomarker...
Background: Multiple sclerosis (MS) is the commonest cause of non-traumatic neurological disability ...
Aim of the study Our main purpose was to investigate if the chronic treatment with the disease-modif...
In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesion...
The pathophysiology of multiple sclerosis (MS) is complex with the presence of inflammation and neur...
Abstract Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous sys...
Natalizumab inhibits the transmigration of immune cells across the blood-brain barrier thus inhibiti...
Objective: To report the relationship between disease activity and health-related quality of life (H...
Background: Natalizumab provides rapid and high-efficacy control of multiple sclerosis disease activ...